Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 274 articles:
HTML format



Single Articles


    July 2021
  1. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    PubMed    


    June 2021
  2. KHAN PY, Franke MF, Hewison C, Seung KJ, et al
    All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04345-2020.
    PubMed     Abstract available


  3. SAAVEDRA B, Mambuque E, Nguenha D, Gomes N, et al
    Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00257-2021.
    PubMed     Abstract available


  4. ORIKIRIZA P, Smith J, Ssekyanzi B, Nyehangane D, et al
    Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.
    Eur Respir J. 2021 Jun 17. pii: 13993003.01116-2021.
    PubMed     Abstract available


  5. VILLA S, Tagliani E, Borroni E, Castellotti PF, et al
    Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: urgency of cross-border, multidimensional, surveillance systems.
    Eur Respir J. 2021 Jun 3. pii: 13993003.00839-2021.
    PubMed    


  6. GUGLIELMETTI L, Varaine F
    The coming-of-age of bedaquiline: a tale with an open ending.
    Eur Respir J. 2021;57.
    PubMed    


    May 2021
  7. PENN-NICHOLSON A, Gomathi SN, Ugarte-Gil C, Meaza A, et al
    A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
    Eur Respir J. 2021 May 28. pii: 13993003.00526-2021.
    PubMed     Abstract available


  8. NOGUERA-JULIAN A, Buonsenso D, Mckenna L, Seddon JA, et al
    Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe.
    Eur Respir J. 2021 May 28. pii: 13993003.01196-2021.
    PubMed    


  9. VELEN K, Shingde RV, Ho J, Fox GJ, et al
    The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.
    Eur Respir J. 2021 May 20. pii: 13993003.00266-2021.
    PubMed     Abstract available


  10. WEE LE, Goh KCM, Conceicao EP, Tan JBX, et al
    Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic.
    Eur Respir J. 2021;57.
    PubMed    


  11. GHOSH S, Breitscheidel L, Lazarevic N, Martin A, et al
    Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  12. MAYNARD-SMITH L, Brown CS, Harris RJ, Hodkinson P, et al
    Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    April 2021
  13. VEZIRIS N, Bonnet I, Morel F, Guglielmetti L, et al
    Impact of the revised definition of extensively drug resistant tuberculosis.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00641-2021.
    PubMed    


  14. MUYOYETA M, Kerkhoff AD, Chilukutu L, Moreau E, et al
    Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.
    Eur Respir J. 2021 Apr 29. pii: 13993003.03999-2020.
    PubMed     Abstract available


  15. VAN DEUN A, Decroo T, Aung KJM, Hossain MA, et al
    Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00783-2021.
    PubMed    


  16. HAMADA Y, Cirillo DM, Matteelli A, Penn-Nicholson A, et al
    Tests for tuberculosis infection: landscape analysis.
    Eur Respir J. 2021 Apr 19. pii: 13993003.00167-2021.
    PubMed     Abstract available


  17. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    PubMed    


  18. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    PubMed    


  19. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    PubMed    


  20. NORDHOLM AC, Lillebaek T
    It is time to optimise the management of latent tuberculosis infection in children.
    Eur Respir J. 2021;57.
    PubMed    


    March 2021
  21. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    PubMed     Abstract available


  22. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    PubMed    


  23. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    PubMed    


  24. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    February 2021
  25. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    PubMed     Abstract available


  26. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    PubMed     Abstract available


  27. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    January 2021
  28. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    PubMed     Abstract available


  29. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  30. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    PubMed    


    December 2020
  31. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    PubMed     Abstract available


    November 2020
  32. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    PubMed     Abstract available


  33. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    PubMed    


  34. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    PubMed    


  35. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    PubMed    


    October 2020
  36. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    PubMed     Abstract available


  37. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    PubMed    


  38. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    PubMed    


    September 2020
  39. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    PubMed    


  40. ALFFENAAR JC, Tiberi S, Cirillo DM, Migliori GB, et al
    Intermittent regimens for tuberculosis treatment: Back to the Future?
    Eur Respir J. 2020;56.
    PubMed    


    August 2020
  41. OHD JN, Hergens MP, Luksha Y, Buxbaum C, et al
    Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018 - a record linkage study of the care cascade.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02255-2020.
    PubMed     Abstract available


  42. MCQUAID CF, Cohen T, Dean AS, Houben RMGJ, et al
    Ongoing challenges to understanding multidrug and rifampicin-resistant tuberculosis in children versus adults.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02504-2020.
    PubMed     Abstract available


  43. KIM HY, Ulbricht E, Ahn YK, Gillooly IS, et al
    Therapeutic drug monitoring practice in patients with active tuberculosis; assessment of opportunities.
    Eur Respir J. 2020 Aug 18. pii: 13993003.02349-2020.
    PubMed    


  44. FEUERRIEGEL S, Kohl TA, Utpatel C, Andres S, et al
    Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex(R)-MycTB.
    Eur Respir J. 2020 Aug 6. pii: 13993003.01796-2020.
    PubMed    


  45. KHURANA AK, Aggarwal D
    The (in)significance of TB and COVID-19 co-infection.
    Eur Respir J. 2020;56.
    PubMed    


    July 2020
  46. TAGLIANI E, Anthony R, Kohl TA, de Neeling A, et al
    Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC pilot study.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02272-2020.
    PubMed     Abstract available


  47. CHEN H, Zhang K
    Insight into impact of COVID-19 epidemic on tuberculosis burden in China.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02710-2020.
    PubMed    


  48. MAGRO P, Formenti B, Marchese V, Gulletta M, et al
    Impact of the SARS Coronavirus 2 epidemic on tuberculosis treatment outcome, Northern Italy.
    Eur Respir J. 2020 Jul 23. pii: 13993003.02665-2020.
    PubMed    


  49. HACKER B, Schonfeld N, Krieger D, Otto-Knapp R, et al
    Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany.
    Eur Respir J. 2020 Jul 6. pii: 13993003.00009-2020.
    PubMed    


  50. AVALIANI Z, Gozalov O, Kuchukhidze G, Skrahina A, et al
    What is behind programmatic treatment outcome definitions for tuberculosis?
    Eur Respir J. 2020;56.
    PubMed    


  51. MOHR-HOLLAND E, Reuter A, Hughes J, Daniels J, et al
    Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
    Eur Respir J. 2020;56.
    PubMed    


    June 2020
  52. LAU A, Sligl W, Sun K, Barrie J, et al
    Incidence and Significance of Venous Thromboembolism in Critically ill Pulmonary Tuberculosis Patients.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01753-2020.
    PubMed    


  53. TADOLINI M, Garcia-Garcia JM, Blanc FX, Borisov S, et al
    On Tuberculosis and COVID-19 co-infection.
    Eur Respir J. 2020 Jun 25. pii: 13993003.02328-2020.
    PubMed    


  54. MIN ONG CW, Migliori GB, Raviglione M, MacGregor-Skinner G, et al
    Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members(#) of ESCMID Study Group for
    Eur Respir J. 2020 Jun 25. pii: 13993003.01727-2020.
    PubMed     Abstract available


  55. KWAK N, Winters N, Campbell JR, Chan ED, et al
    Changes in treatment for multidrug-resistant tuberculosis according to national income.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01394-2020.
    PubMed     Abstract available


  56. MCQUAID CF, McCreesh N, Read JM, Sumner T, et al
    The potential impact of COVID-19-related disruption on tuberculosis burden.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01718-2020.
    PubMed    


  57. VISCA D, Tiberi S, Pontali E, Spanevello A, et al
    Tuberculosis in the time of COVID-19: quality of life and digital innovation.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01998-2020.
    PubMed    


  58. STOCHINO C, Villa S, Zucchi P, Parravicini P, et al
    Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital.
    Eur Respir J. 2020 Jun 1. pii: 13993003.01708-2020.
    PubMed    


  59. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    The looming threat of bedaquiline resistance in tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


    May 2020
  60. GAFAR F, Ochi T, Van't Boveneind-Vrubleuskaya N, Akkerman OW, et al
    Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data.
    Eur Respir J. 2020 May 29. pii: 13993003.01086-2020.
    PubMed     Abstract available


  61. NDJEKA N, Conradie F, Meintjes G, Reuter A, et al
    Responding to SARS-CoV-2 in South Africa: What can we learn from drug-resistant tuberculosis?
    Eur Respir J. 2020 May 29. pii: 13993003.01369-2020.
    PubMed    


  62. TADOLINI M, Codecasa LR, Garcia-Garcia JM, Blanc FX, et al
    Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Eur Respir J. 2020 May 26. pii: 13993003.01398-2020.
    PubMed    


  63. SAUNDERS MJ, Evans CA
    COVID-19, tuberculosis, and poverty: preventing a perfect storm.
    Eur Respir J. 2020 May 22. pii: 13993003.01348-2020.
    PubMed    


  64. HARAKA F, Schumacher SG, Ross A, Mantsoki A, et al
    Effect of history of tuberculosis on specificity of Xpert MTB/RIF.
    Eur Respir J. 2020 May 13. pii: 13993003.00343-2020.
    PubMed    


  65. VAN DEN ELSEN SHJ, Akkerman OW, Wessels M, Jongedijk EM, et al
    Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
    Eur Respir J. 2020 May 12. pii: 13993003.00803-2020.
    PubMed    


  66. DATTA S, Gilman RH, Montoya R, Quevedo Cruz L, et al
    Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.
    Eur Respir J. 2020 May 4. pii: 13993003.00495-2019.
    PubMed     Abstract available


  67. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    PubMed    


  68. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    PubMed    


    April 2020
  69. BASU ROY R, Thee S, Blazquez-Gamero D, Falcon-Neyra L, et al
    Performance of immune-based and microbiological tests in children with TB meningitis in Europe - a multi-center Paediatric Tuberculosis Network European Trials Group (ptbnet) study.
    Eur Respir J. 2020 Apr 16. pii: 13993003.02004-2019.
    PubMed     Abstract available


  70. BASHAM CA, Cook VJ, Johnston JC
    Towards a "fourth 90": A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985-2015.
    Eur Respir J. 2020 Apr 7. pii: 13993003.00384-2020.
    PubMed    


  71. SPRUIJT I, Erkens C, van den Hof S, Cobelens F, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  72. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  73. ALAGNA R, Besozzi G, Codecasa LR, Gori A, et al
    Celebrating World Tuberculosis Day at the time of COVID-19.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  74. FALZON D, Schunemann HJ, Zignol M, Mirzayev F, et al
    WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.
    Eur Respir J. 2020;55.
    PubMed    


  75. GUGLIELMETTI L, Huerga H, Khan U, Varaine F, et al
    WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?
    Eur Respir J. 2020;55.
    PubMed    


  76. CEGIELSKI JP, Nahid P, Sotgiu G
    The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  77. GEBRESELASSIE N, Hutubessy R, Vekemans J, den Boon S, et al
    The case for assessing the full value of new tuberculosis vaccines.
    Eur Respir J. 2020;55.
    PubMed    


  78. FIEBIG L, Beyene N, Burny R, Fast CD, et al
    From pests to tests: training rats to diagnose tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  79. HAMADA Y, Figueroa C, Martin-Sanchez M, Falzon D, et al
    The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


    February 2020
  80. NIMMO C, Millard J, Brien K, Moodley S, et al
    Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.
    Eur Respir J. 2020 Feb 14. pii: 13993003.02383-2019.
    PubMed    


    January 2020
  81. RONALD LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, et al
    Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs.
    Eur Respir J. 2020 Jan 24. pii: 13993003.02048-2019.
    PubMed     Abstract available


  82. FROBERG G, Jansson L, Nyberg K, Obasi B, et al
    Screening and treatment of tuberculosis among pregnant women in Stockholm 2016-2017.
    Eur Respir J. 2020 Jan 16. pii: 13993003.00851-2019.
    PubMed     Abstract available


    December 2019
  83. JONSSON J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J, et al
    Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01886-2019.
    PubMed     Abstract available


  84. DE VRIES G, Commandeur S, Erkens C, Haddad W, et al
    Towards selective tuberculosis screening of people in prison in a low-incidence country.
    Eur Respir J. 2019 Dec 20. pii: 13993003.02209-2019.
    PubMed    


  85. STEK C, Allwood B, Du Bruyn E, Buyze J, et al
    The effect of HIV-associated tuberculosis, tuberculosis-IRIS, and prednisone on lung function.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01692-2019.
    PubMed     Abstract available


  86. RUESEN C, Chaidir L, Ugarte-Gil C, van Ingen J, et al
    Diabetes is associated with genotypically drug-resistant tuberculosis.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01891-2019.
    PubMed    


  87. BOMANJI J, Sharma R, Mittal BR, Gambhir S, et al
    PET/CT features of Extrapulmonary Tuberculosis at first clinical presentation - a cross-sectional observational (18)F-FDG imaging study across six countries.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01959-2019.
    PubMed     Abstract available


  88. GENESTET C, Paret R, Pichat C, Berland JL, et al
    Routine survey of Mycobacterium tuberculosis isolates reveals nosocomial transmission.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01888-2019.
    PubMed    


  89. LEE SW, Kang YA, Jin CE, Kim HC, et al
    Gene-based diagnosis of tuberculosis with a new-generation pathogen enrichment technique.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01885-2019.
    PubMed    


    November 2019
  90. KERKHOFF AD, Sossen B, Schutz C, Reipold EI, et al
    Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.
    Eur Respir J. 2019 Nov 7. pii: 13993003.01259-2019.
    PubMed    


    October 2019
  91. OLAYANJU O, Esmail A, Limberis J, Dheda K, et al
    A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis.
    Eur Respir J. 2019 Oct 16. pii: 13993003.01181-2019.
    PubMed     Abstract available


  92. BORISOV S, Danila E, Maryandyshev A, Dalcolmo M, et al
    Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
    Eur Respir J. 2019 Oct 10. pii: 13993003.01522-2019.
    PubMed     Abstract available


  93. DIEL R, Schluger NW
    Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
    Eur Respir J. 2019;54.
    PubMed    


  94. CAMINERO JA, Garcia-Basteiro AL, Rendon A, Piubello A, et al
    The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.
    Eur Respir J. 2019;54.
    PubMed    


  95. ZELLWEGER JP
    Screening migrants for tuberculosis and latent TB infection: the reward will come later.
    Eur Respir J. 2019;54.
    PubMed    


    September 2019
  96. AHMAD BB, Kristensen KL, Glenthoj JP, Poulsen A, et al
    Latent tuberculosis infection among minor asylum seekers in Denmark.
    Eur Respir J. 2019 Sep 26. pii: 13993003.01688-2019.
    PubMed    


  97. EL ACHKAR S, Demanche C, Osman M, Rafei R, et al
    Zoonotic tuberculosis in humans assessed by next-generation sequencing: an 18-month nationwide study in Lebanon.
    Eur Respir J. 2019 Sep 26. pii: 13993003.00513-2019.
    PubMed    


  98. SPRUIJT I, Tesfay Haile D, Suurmond J, van den Hof S, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed methods study.
    Eur Respir J. 2019 Sep 19. pii: 13993003.00861-2019.
    PubMed     Abstract available


  99. GAFAR F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, et al
    Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in The Netherlands.
    Eur Respir J. 2019 Sep 12. pii: 13993003.01402-2019.
    PubMed     Abstract available


  100. SOTGIU G, Goletti D, Matteelli A
    Global tuberculosis prevention: should we start from the beginning?
    Eur Respir J. 2019;54.
    PubMed    


  101. REEVE BWP, Centis R, Theron G
    Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals.
    Eur Respir J. 2019;54.
    PubMed    


    August 2019
  102. DIEL R, Kohl TA, Mauer F, Merker M, et al
    Accuracy of whole genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany.
    Eur Respir J. 2019 Aug 29. pii: 13993003.01154-2019.
    PubMed    


  103. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Tuberculosis among asylum-seekers in Milan, Italy: Epidemiological analysis and evaluation of interventions.
    Eur Respir J. 2019 Aug 14. pii: 13993003.00896-2019.
    PubMed     Abstract available


    July 2019
  104. GARCIA-BASTEIRO AL, Hurtado JC, Castillo P, Fernandes F, et al
    Unmasking the hidden tuberculosis mortality burden in a large postmortem study in Maputo Central Hospital, Mozambique.
    Eur Respir J. 2019 Jul 25. pii: 13993003.00312-2019.
    PubMed     Abstract available


    June 2019
  105. GUPTA RK, Rosenberg G, Eriksen J, Lipman M, et al
    Tuberculosis following Renal Transplantation in England, Wales and Northern Ireland: A National Registry-based Cohort Study.
    Eur Respir J. 2019 Jun 27. pii: 13993003.02245-2018.
    PubMed    


  106. COHEN A, Mathiasen VD, Schon T, Wejse C, et al
    The global prevalence of latent tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2019 Jun 20. pii: 13993003.00655-2019.
    PubMed     Abstract available


  107. MELSEW YA, Cheng AC, McBryde ES, Denholm JT, et al
    Profiles of tuberculosis disease activation among contacts of patients with tuberculosis.
    Eur Respir J. 2019 Jun 4. pii: 13993003.00353-2019.
    PubMed    


  108. SNOW KJ, Sawyer SM, Denholm JT, Graham SM, et al
    Explaining variation in the burden of child and adolescent tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


    May 2019
  109. POORAN A, Davids M, Nel A, Shoko A, et al
    IL-4 subverts mycobacterial containment in M. tuberculosis-infected human macrophages.
    Eur Respir J. 2019 May 16. pii: 13993003.02242-2018.
    PubMed     Abstract available


  110. VASILYEVA I, Mariandyshev A, Kazennyy B, Davidaviciene E, et al
    Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Eur Respir J. 2019 May 16. pii: 13993003.02208-2018.
    PubMed    


  111. WALKER IF, Shi O, Hicks J, Elsey H, et al
    Analysis of loss to follow up in 4,099 multidrug-resistant pulmonary tuberculosis patients.
    Eur Respir J. 2019 May 9. pii: 13993003.00353-2018.
    PubMed     Abstract available


  112. DEKKERS BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, et al
    Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.
    Eur Respir J. 2019 May 2. pii: 13993003.00373-2019.
    PubMed    


  113. MARTINEZ L, Verma R, Croda J, Horsburgh CR, et al
    Detection, survival and infectious potential of Mycobacterium tuberculosis in the environment: A review of the evidence and epidemiological implications.
    Eur Respir J. 2019 May 2. pii: 13993003.02302-2018.
    PubMed     Abstract available


  114. CHEN YY, Pan SW, Shen HS, Chuang FY, et al
    Declining trend in incidence of tuberculosis in adolescents and young adults in Taiwan.
    Eur Respir J. 2019;53.
    PubMed    


    April 2019
  115. MIGLIORI GB, Nardell E, Yedilbayev A, D'Ambrosio L, et al
    Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
    Eur Respir J. 2019 Apr 25. pii: 13993003.00391-2019.
    PubMed     Abstract available


  116. FURIN J, Sotgiu G
    Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?
    Eur Respir J. 2019;53.
    PubMed    


    March 2019
  117. LANCIONI C, Swarbrick GM, Park B, Nyendak M, et al
    Recognition of CD8(+) T cell Epitopes to Identify Adults with Pulmonary Tuberculosis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.02053-2018.
    PubMed    


  118. VISCA D, Zampogna E, Sotgiu G, Centis R, et al
    Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.
    Eur Respir J. 2019;53.
    PubMed    


  119. GEBRESELASSIE N, Falzon D, Zignol M, Kasaeva T, et al
    Tuberculosis research questions identified through the WHO policy guideline development process.
    Eur Respir J. 2019;53.
    PubMed    


  120. CHAN PC, Lee PH, Lu MJ, Huang YC, et al
    Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly.
    Eur Respir J. 2019;53.
    PubMed    


    February 2019
  121. APRIANI L, McAllister S, Sharples K, Alisjahbana B, et al
    Latent tuberculosis infection in health care workers in low and middle-income countries: an updated systematic review.
    Eur Respir J. 2019 Feb 20. pii: 13993003.01789-2018.
    PubMed     Abstract available


  122. JOLLIFFE DA, Ganmaa D, Wejse C, Raqib R, et al
    Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.
    Eur Respir J. 2019 Feb 6. pii: 13993003.02003-2018.
    PubMed     Abstract available


    January 2019
  123. PAGE ID, Byanyima R, Hosmane S, Onyachi N, et al
    Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.
    Eur Respir J. 2019 Jan 31. pii: 13993003.01184-2018.
    PubMed     Abstract available


  124. VAN LETH F, Brinkmann F, Cirillo DM, Dheda K, et al
    The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
    Eur Respir J. 2019;53.
    PubMed    


  125. ABUBAKAR I, Lipman M
    Reducing loss to follow-up during treatment for drug-resistant tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


  126. ROSALES-KLINTZ S, Bruchfeld J, Haas W, Heldal E, et al
    Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.
    Eur Respir J. 2019;53.
    PubMed    


    December 2018
  127. MENZIES D, Trajman A
    New short regimens for latent tuberculosis treatment: safety first!
    Eur Respir J. 2018;52.
    PubMed    


    November 2018
  128. FROBERG G, Jansson L, Bruchfeld J
    Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice.
    Eur Respir J. 2018 Nov 8. pii: 13993003.01128-2018.
    PubMed    


    October 2018
  129. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating the prevalence of latent tuberculosis in a low incidence setting: Australia.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01218-2018.
    PubMed     Abstract available


  130. NDJEKA N, Schnippel K, Master I, Meintjes G, et al
    High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01528-2018.
    PubMed     Abstract available


  131. GOLETTI D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, et al
    Can we predict tuberculosis cure? Current tools available.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01089-2018.
    PubMed     Abstract available


  132. GAO L, Zhang H, Xin H, Liu J, et al
    Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01470-2018.
    PubMed     Abstract available


  133. COLLIN SM, de Vries G, Lonnroth K, Migliori GB, et al
    Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01449-2018.
    PubMed     Abstract available


  134. LAW S, Daftary A, O'Donnell M, Padayatchi N, et al
    Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01030-2018.
    PubMed     Abstract available


  135. GANDHI NR, Brust JCM, Shah NS
    A new era for treatment of drug-resistant tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


  136. RUHWALD M, Diel R
    Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


    September 2018
  137. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ, et al
    European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following publication of the new World Health Organization recommendations.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01617-2018.
    PubMed    


  138. CABIBBE AM, Walker TM, Niemann S, Cirillo DM, et al
    Whole Genome Sequencing of Mycobacterium tuberculosis.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01163-2018.
    PubMed     Abstract available


    August 2018
  139. NSENGIYUMVA NP, Mappin-Kasirer B, Oxlade O, Bastos M, et al
    Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
    Eur Respir J. 2018 Aug 30. pii: 13993003.01363-2018.
    PubMed     Abstract available


  140. KIK SV, Schumacher S, Maria Cirillo D, Churchyard G, et al
    An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00946-2018.
    PubMed     Abstract available


  141. AULD SC, Sarita Shah N, Mathema B, Brown TS, et al
    XDR tuberculosis in South Africa: genomic evidence supporting transmission in communities.
    Eur Respir J. 2018 Aug 16. pii: 13993003.00246-2018.
    PubMed     Abstract available


  142. UZORKA JW, Delfos NM, Witte AMC, Scheper H, et al
    Tuberculosis after a borderline QuantiFERON result during screening before infliximab.
    Eur Respir J. 2018;52.
    PubMed    


    June 2018
  143. PONTALI E, Sotgiu G, Tiberi S, Tadolini M, et al
    Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Eur Respir J. 2018 Jun 14. pii: 13993003.00934-2018.
    PubMed    


  144. GUGLIELMETTI L, Tiberi S, Burman M, Kunst H, et al
    QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study.
    Eur Respir J. 2018 Jun 7. pii: 13993003.00537-2018.
    PubMed    


    May 2018
  145. DOBLER CC, Fox GJ, Douglas P, Viney KA, et al
    Screening for tuberculosis in migrants and visitors from high incidence settings: present and future perspectives.
    Eur Respir J. 2018 May 24. pii: 13993003.00591-2018.
    PubMed     Abstract available


  146. ASSEFA Y, Assefa Y, Woldeyohannes S, Hamada Y, et al
    Three-month daily Rifampicin and Isoniazid compared to six or nine-month Isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Eur Respir J. 2018 May 10. pii: 13993003.00395-2018.
    PubMed    


  147. MOHR E, Hughes J, Reuter A, Trivino Duran L, et al
    Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.
    Eur Respir J. 2018 May 3. pii: 13993003.00017-2018.
    PubMed     Abstract available


  148. MUSTAZZOLU A, Borroni E, Maria Cirillo D, Giannoni F, et al
    Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009-2016.
    Eur Respir J. 2018 May 3. pii: 13993003.00070-2018.
    PubMed    


  149. ABUBAKAR I, Matteelli A, de Vries G, Zenner D, et al
    Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.
    Eur Respir J. 2018;51.
    PubMed    


  150. VILLANUEVA P, Neth O, Ritz N, Tebruegge M, et al
    Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
    Eur Respir J. 2018;51.
    PubMed    



  151. "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey." Dodge R. Lim, Anna S. Dean, Mary Rosary Taguinod-Santiago, Angeli Borbe-Reyes, Andrea Maurizio Cabibbe, Matteo Zignol, Ra
    Eur Respir J. 2018;51.
    PubMed    


    April 2018
  152. OLAYANJU O, Limberis J, Esmail A, Oelofse S, et al
    LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00544-2018.
    PubMed    


  153. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, Centis R, et al
    ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.
    Eur Respir J. 2018 Apr 20. pii: 13993003.02678-2017.
    PubMed     Abstract available


  154. CABIBBE AM, Trovato A, De Filippo MR, Ghodousi A, et al
    Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00387-2018.
    PubMed    


  155. CHANG KC, Chung-Ching Leung E, Law WS, Leung WM, et al
    Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00159-2018.
    PubMed    


    March 2018
  156. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed    


  157. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Abstract available


  158. LIM DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, et al
    Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.
    Eur Respir J. 2018 Mar 1. pii: 13993003.02571-2017.
    PubMed    


  159. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  160. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed    


  161. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed    


  162. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed    


  163. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed    


  164. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed    


  165. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed    


  166. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  167. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


    February 2018
  168. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed    


  169. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed    


  170. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed    


  171. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  172. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  173. GARCIA-BASTEIRO AL, Schaaf HS, Diel R, Migliori GB, et al
    Adolescents and young adults: a neglected population group for tuberculosis surveillance.
    Eur Respir J. 2018;51.
    PubMed    


  174. ALVAREZ-URIA G, Midde M
    Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
    Eur Respir J. 2018;51.
    PubMed    


  175. SNOW KJ, Sismanidis C, Denholm J, Sawyer SM, et al
    The incidence of tuberculosis among adolescents and young adults: a global estimate.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  176. HEYCKENDORF J, van Leth F, Kalsdorf B, Olaru ID, et al
    Relapse-free cure from multidrug-resistant tuberculosis in Germany.
    Eur Respir J. 2018;51.
    PubMed    


  177. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    Should gatifloxacin be included in the model list of essential medicines?
    Eur Respir J. 2018;51.
    PubMed    


    January 2018
  178. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed    


  179. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  180. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  181. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  182. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed    


  183. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed    


  184. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed    


    December 2017
  185. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed    


  186. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed    


  187. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  188. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    November 2017
  189. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed    


  190. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed    


  191. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  192. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed    


  193. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed    


  194. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed    


    October 2017
  195. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed    


  196. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  197. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed    


  198. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed    


  199. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed    


    September 2017
  200. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed    


    August 2017
  201. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed    


  202. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed    


  203. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed    


  204. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    July 2017
  205. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed    


  206. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed    


  207. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed    


  208. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  209. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  210. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  211. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed    


  212. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  213. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed    


    June 2017
  214. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed    


  215. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  216. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  217. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed    


  218. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    May 2017
  219. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  220. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed    


  221. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed    


  222. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    April 2017
  223. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  224. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed    


  225. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed    


  226. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed    


  227. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  228. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


    March 2017
  229. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed    


  230. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed    


  231. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  232. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  233. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed    


  234. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed    


  235. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed    


  236. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed    


  237. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  238. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed    


  239. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed    


  240. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  241. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed    


  242. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed    


  243. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    February 2017
  244. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed    


    January 2017
  245. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed    


  246. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed    


  247. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  248. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed    


  249. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed    


  250. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available



  251. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed    


  252. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed    


    December 2016
  253. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed    


  254. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Abstract available


  255. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed    


    November 2016
  256. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Abstract available


  257. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed    


  258. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed    


  259. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed    


  260. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed    


  261. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed    


  262. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Abstract available


  263. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed    


  264. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed    


    October 2016
  265. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Abstract available


  266. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed    


  267. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Abstract available


  268. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed    


  269. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed    


    September 2016
  270. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Abstract available


    April 2016
  271. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Abstract available


    March 2016
  272. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Abstract available


    January 2016
  273. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed    


  274. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: